51,000 Americans will be diagnosed with pancreatic cancer this year. Roughly 45,000 will die from it. The five-year survival rate has not meaningfully changed since 2000. On June 11, a company called Immuneering dosed its first Phase 3 patient.
Immuneering Corporation Doses First Patient in Phase 3 MAPKeeper 301 Pancreatic Cancer Trial
Immuneering Corporation (Nasdaq: IMRX) announced on June 11 that the first patient had been dosed in MAPKeeper 301, a global Phase 3 trial evaluating atebimetinib (a MEK inhibitor that uses intermittent high-dose delivery rather than chronic dosing, designed to hit the MAPK pathway hard enough to suppress tumor growth while slowing the resistance that typically develops against chronically administered MEK inhibitors) plus modified gemcitabine/nab-paclitaxel against standard gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer.
The Phase 2a data behind this trial: 17.3-month median overall survival. 64% of patients still alive at 12 months. Standard chemotherapy delivers 11 to 12 months median OS in this setting. Those numbers are why MAPKeeper 301 exists.
The lead investigator is Dr. Eileen O’Reilly of Memorial Sloan Kettering. The trial is registered at ClinicalTrials.gov under NCT07562152. Topline data is expected mid-2028.
Cash runway is the operational risk. A global Phase 3 in pancreatic cancer is expensive. Any update on financing, partnerships, or burn rate will tell you more about whether this trial reaches completion than any interim clinical data.
Context Therapeutics Posts Positive Phase 1 CTIM-76 Data in Platinum-Resistant Ovarian Cancer
Context Therapeutics Inc. (Nasdaq: CNTX) released interim Phase 1 data for CTIM-76 on June 15, one day outside this window. The data is worth knowing. It was presented at the ESMO Gynaecological Cancers Congress 2026 with a May 29 data cutoff.
CTIM-76 is a CLDN6 x CD3 T-cell engaging bispecific antibody. CLDN6 (Claudin 6, a protein found on certain cancer cells but largely absent from normal adult tissue, which makes it an attractive target for therapies that need to distinguish tumor from healthy cells) is expressed in approximately 70% of platinum-resistant ovarian cancers. That patient population has exhausted standard platinum-based chemotherapy and has very few remaining options.
At active doses, anti-tumor activity was observed. Cytokine release syndrome was Grade 1 in 11% of patients. No higher-grade CRS. The pharmacokinetics support moving to every-three-week dosing in H2 2026, which reduces patient burden significantly.
CTIM-76 holds FDA Fast Track designation. Cash runway extends into mid-2027. Context also has CT-95 targeting mesothelin and CT-202 targeting Nectin-4 in development behind CTIM-76.
Elicio Therapeutics Phase 2 AMPLIFY-7P Misses Primary Endpoint but Shows Early Activity in Pancreatic Cancer
Also June 15. Elicio Therapeutics (Nasdaq: ELTX) reported that the Phase 2 AMPLIFY-7P study of ELI-002 7P in adjuvant mKRAS-driven pancreatic ductal adenocarcinoma (patients whose cancer has been surgically removed or irradiated, where the drug aims to prevent recurrence by targeting KRAS-mutated cells that may remain in the body) did not meet its primary disease-free survival endpoint in the intent-to-treat population.
Landmark analyses during active ELI-002 7P treatment showed a 14% absolute DFS benefit at both the 3-month and 6-month marks. The treatment-arm separation persisted through 9 months. The drug appears to do something while patients are receiving it. Whether that effect is durable enough across the full population to move a survival endpoint is the question the trial could not answer.
Elicio is evaluating strategic financing and partnership options. Cash runs into Q4 2026. No Phase 3 decision has been announced. The company has not disclosed whether it will proceed without additional data or additional capital. Filings on SEC EDGAR.
Upcoming Catalysts: Immuneering MAPKeeper 301 Enrollment, Context Therapeutics Q3W Dosing, Elicio Financing Decision
Immuneering: enrollment pace and site activation across the global MAPKeeper 301 network. Topline is mid-2028 but operational execution is visible before then.
Context Therapeutics: Q3W dosing expansion in H2 2026 is the next clinical event. An updated CTIM-76 dataset at a major oncology conference before year end is likely.
Elicio: financing announcement or strategic partnership is the near-term catalyst. No capital, no Phase 3. The post-hoc signal is interesting enough that a partner might see value here. The Q4 2026 cash runway is not.
Sources
- GlobeNewswire / BioSpace: Immuneering first patient dosed MAPKeeper 301, June 11, 2026
- StockTitan: Immuneering IMRX Phase 3 first patient, June 11, 2026
- Immuneering IR: Phase 2a 17.3-month median OS press release, May 21, 2026
- GlobeNewswire / BioSpace: Context Therapeutics Phase 1 CTIM-76 interim data, June 15, 2026
- StockTitan SEC 8-K: Context Therapeutics CNTX CTIM-76 Phase 1, June 15, 2026
- GlobeNewswire / BioSpace: Elicio Therapeutics Phase 2 AMPLIFY-7P results, June 15, 2026
Editorial Disclosure
This roundup is based entirely on publicly available information including press releases, SEC filings, and clinical trial disclosures. Securities discussed include Immuneering Corporation (Nasdaq: IMRX), Context Therapeutics Inc. (Nasdaq: CNTX), and Elicio Therapeutics, Inc. (Nasdaq: ELTX). aktiego.com has not received any compensation from any company mentioned, their management, investor relations representatives, or any third party. No staff member or principal of aktiego.com holds a position in any security mentioned at the time of publication. Immuneering press release date verified via GlobeNewswire June 11, 2026. Context Therapeutics and Elicio Therapeutics press releases are dated June 15, 2026, one day after the close of the primary coverage window; both are included given the clinical significance of the data. All drugs are investigational and not FDA approved for the indications discussed. Atebimetinib Phase 3 topline data is not expected until mid-2028. CTIM-76 is in Phase 1; interim data is early-stage and subject to change. AMPLIFY-7P did not meet its pre-specified primary DFS endpoint in the intent-to-treat population; the post-hoc analyses described are exploratory and were not pre-specified. Elicio reported a cash runway extending only into Q4 2026 and is actively seeking financing; the company may be unable to advance its pipeline without additional capital. These are speculative investments carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.
